Safety and efficacy of everolimus in Chinese patients with metastatic renal cell carcinoma resistant to vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapy: an open-label phase 1b study

被引：0
|
作者：
Jun Guo
Yiran Huang
Xu Zhang
Fangjian Zhou
Yinghao Sun
Shukui Qin
Zhangqun Ye
Hui Wang
Annette Jappe
Patrick Straub
Nicoletta Pirotta
Sven Gogov
机构：
[1] Peking University Cancer Hospital and Institute,
[2] Shanghai Renji Hospital,undefined
[3] The General Hospital of PLA,undefined
[4] Sun Yat-sen University Cancer Center,undefined
[5] Shanghai Changhai Hospital,undefined
[6] Nanjing Bayi Hospital,undefined
[7] Wuhan Tongji Hospital,undefined
[8] Beijing Novartis Pharma Company,undefined
[9] Ltd.,undefined
[10] Novartis Pharma AG,undefined
[11] Novartis Pharma AG,undefined
[12] Novartis Pharma AG,undefined
[13] Novartis Pharma AG,undefined
来源：
BMC Cancer | / 13卷
关键词：
Asian; Everolimus; mTOR inhibitor; Renal cell cancer; Sunitinib; Sorafenib;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [21] Efficacy and safety of third-line molecular-targeted therapy in metastatic renal cell carcinoma resistant to first-line vascular endothelial growth factor receptor tyrosine kinase inhibitor and second-line therapy
    Hiroki Ishihara
    Toshio Takagi
    Tsunenori Kondo
    Hidekazu Tachibana
    Kazuhiko Yoshida
    Kenji Omae
    Junpei Iizuka
    Hirohito Kobayashi
    Kazunari Tanabe
    International Journal of Clinical Oncology, 2018, 23 : 559 - 567
  • [22] Patient-Reported Outcomes in a Phase III Study of Everolimus Versus Placebo in Patients with Metastatic Carcinoma of the Kidney That Has Progressed on Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy
    Beaumont, Jennifer L.
    Butt, Zeeshan
    Baladi, Jeanfrancois
    Motzer, Robert J.
    Haas, Tomas
    Hollaender, Norbert
    Kay, Andrea
    Cella, David
    ONCOLOGIST, 2011, 16 (05): : 632 - 640
  • [23] Everolimus for Korean patients with metastatic renal cell carcinoma who have failed initial treatment of a vascular endothelial growth factor (VEGF): Tyrosine kinase inhibitor (TKI).
    Park, Kwonoh
    Ahn, Jin-Hee
    Song, Cheryn
    Hong, Jun Hyuk
    Kim, Choung-Soo
    Ahn, Hanjong
    Lee, Jae-Lyun
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [24] EVEROLIMUS IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA WHO PROGRESS AFTER INITIAL VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-TYROSINE KINASE INHIBITOR (VEGFR-TKI) THERAPY: UK RESULTS FROM THE REACT TRIAL ON BEHALF OF THE UK REACT INVESTIGATORS
    Chowdhury, S.
    Larkin, J.
    ANNALS OF ONCOLOGY, 2012, 23 : 271 - 272
  • [25] A phase 1b, open-label, safety, tolerability, and efficacy study of HC-7366 in combination with belzutifan in patients with advanced or metastatic renal cell carcinoma (NCT06234605).
    Bupathi, Manojkumar
    Garmezy, Benjamin
    Mckay, Rana R.
    Ornstein, Moshe C.
    Figlin, Robert A.
    Picus, Joel
    Rank, Brian H.
    Barata, Pedro C.
    Hammers, Hans J.
    Hutson, Thomas E.
    Lam, Elaine T.
    Tykodi, Scott S.
    Zhao, Song
    Emamekhoo, Hamid
    Chisamore, Michael Jon
    Mattson, Paulette
    Holm, Megan
    Iglesias, Jose Luis
    Motzer, Robert J.
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (5_SUPPL) : TPS609 - TPS609
  • [26] Safety and clinical activity of vascular endothelial growth factor receptor (VEGFR)-tyrosine kinase inhibitors after programmed cell death 1 inhibitor treatment in patients with metastatic clear cell renal cell carcinoma
    Nadal, R.
    Amin, A.
    Geynisman, D. M.
    Voss, M. H.
    Weinstock, M.
    Doyle, J.
    Zhang, Z.
    Viudez, A.
    Plimack, E. R.
    McDermott, D. F.
    Motzer, R.
    Rini, B.
    Hammers, H. J.
    ANNALS OF ONCOLOGY, 2016, 27 (07) : 1304 - 1311
  • [27] Cardiotoxicity of Selected Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients with Renal Cell Carcinoma
    Franczyk, Beata
    Rysz, Jacek
    Lawinski, Janusz
    Cialkowska-Rysz, Aleksandra
    Gluba-Brzozka, Anna
    BIOMEDICINES, 2023, 11 (01)
  • [28] International, expanded access program of everolimus in patients with metastatic renal cell carcinoma (mRCC) who progressed after previous vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapy (VEGFr-TKI): Subanalysis from emerging growth market (EGM) countries
    Lee, Se-Hoon
    Buyukberber, Suleyman
    Ou, Yen-Chuan
    Shapiro, Jeremy David
    Panneerselvam, Ashok
    Arikan, Ozlem Ocak
    Xue, Hong-Ling
    Rusakov, Igor
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [29] Establishment of the classifier for a response to vascular endothelial growth factor (VEGF)-tyrosine kinase inhibitor (TKI) in metastatic renal cell carcinoma
    Go, Heounjeong
    Kang, Mun Jung
    Kim, Pil-Jong
    Park, Ja-Min
    Lee, Jae-Lyun
    Park, Ji Young
    Cho, Yong Mee
    CANCER RESEARCH, 2016, 76
  • [30] A Phase 1b, Open-Label, Safety, Tolerability, and Efficacy Study of HC-7366 in Combination with Belzutifan (WELIREG™) in Patients with Advanced or Metastatic Renal Cell Carcinoma, NCT06234605
    McKay, Rana R.
    Garmezy, Ben
    Barata, Pedro
    Ornstein, Moshe
    Shah, Neil J.
    Hammers, Hans
    Hutson, Thomas E.
    Chisamore, Michael
    Karim, Dhamina
    Mattson, Paulette
    Lightcap, Eric
    Drees, Jeremy
    Harrison, Ben
    Holm, Megan
    Bose, Nandita
    Thomas, Cherry T.
    Motzer, Robert J.
    ONCOLOGIST, 2024, 29 : S13 - S13
12345